Swiss Roche will buy pharmaceutical company Telavant for $7.25 billion
[ad_1]
Swiss pharmaceutical manufacturer Roche Holding has entered into an agreement with Roivant Sciences and Pfizer to purchase their joint venture Telavant Holdings. should from a company press release.
The deal includes the rights to develop, manufacture and sell in the US and Japan the drug RVT-3101 for the treatment of inflammatory bowel diseases and many other diseases, the statement said. In other countries, Pfizer will retain the right to sell the drug. Roche will also have the opportunity to collaborate with Pfizer on the development of the next generation drug p40/TL1A.
According to the agreement, the transaction amount will be $7.25 billion – $7.1 billion in advance and another $150 million upon achieving certain goals for the drugs being developed. The transaction is expected to close in the fourth quarter of 2023 or the first quarter of 2024.
Roche was founded in 1896 in Switzerland. The group also includes the American Genentech and the Japanese Chugai Pharmaceutical. The company specializes in the development of drugs in the field of oncology, virology, transplantology, etc.
After the start of the special operation in Ukraine, Roche suspended new research in Russia. In September Vedomosti wrotethat over the past year Roche has increased supplies to public medical organizations – from 6.03 to 9.94%.
[ad_2]
Source link
